Dechert Advises Aquestive Therapeutics on Pricing of $75M Underwritten Public Offering of Common Stock
March 23, 2024
March 23, 2024
PHILADELPHIA, Pennsylvania, March 23 -- Dechert, a law firm, issued the following news:
Dechert recently advised Aquestive Therapeutics, Inc. on the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of US$4.50 per share.
The sale, announced on Tuesday, March 19, is expected to generate gross proceeds of approximately US$75 million for Aquestive, before accounting for underwriting discounts, commissions and oth . . .
Dechert recently advised Aquestive Therapeutics, Inc. on the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of US$4.50 per share.
The sale, announced on Tuesday, March 19, is expected to generate gross proceeds of approximately US$75 million for Aquestive, before accounting for underwriting discounts, commissions and oth . . .